Assessment of prostate cancer
US5994071A · kind A · utility
Assignees
Inventors
Key dates
| Filing date | Apr 4, 1997 |
| Grant date | Nov 30, 1999 |
| Priority date | — |
| Expiry date | Apr 4, 2017 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S436/813
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
A method of determining the severity of prostatic cancer includes measuring the level of amplification of the HER-2/neu gene in a sample of prostate tissue by fluorescence in-situ hybridization and comparing the measured level of amplification of the HER-2/neu gene in the sample with the level of HER-2/neu gene in normal prostate tissue. A method for determining treatment for a patient afflicted with prostate cancer includes determining whether the number of copies of HER-2/neu gene in prostate cells from the patient exceeds four by using fluorescence in-situ hybridization and aggressively treating such patient having prostate cells with five or more copies of the HER-2/neu gene.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.